235

2008; 35(6): 995-1001. 14. Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian pa- tients. Medicine (Baltimore). 2013; 92(2): 92-97. 15. Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheuma- toid arthritis. Arthritis Rheum. 2006; 54(9): 2776-2783. 16. Singh JA, SaagKG, Bridges SL Jr., et al. 2015AmericanCol- lege of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016; 68(1): 1-25. 17. Verschueren P, De CockD, Corluy L, et al. Methotrexate in combinationwith otherDMARDs is not superior tomethotrex- ate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann RheumDis. 2015; 74(1): 27-34. 18. Klareskog L, van der Heijde D, de Jager JP, et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Pa- tient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: dou- ble-blind randomised controlled trial. Lancet. 2004; 363(9410): 675-681. 19. Anderson JJ,WellsG, VerhoevenAC, FelsonDT. Factors pre- dicting response to treatment in rheumatoid arthritis: the impor- tance of disease duration. Arthritis Rheum. 2000; 43(1): 22-29. 20. Egsmose C, Lund B, Borg G, et al. Patients with rheuma- toid arthritis benefit fromearly 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheuma- tol. 1995; 22(12): 2208-2213. 21. Nell VP, Machold KP, Eberl G, StammTA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004; 43(7): 906-914. 22. van der LindenMP, le Cessie S, Raza K, et al. Long-term im- pact of delay in assessment of patients with early arthritis. Arthri- tis Rheum. 2010; 62(12): 3537-3546. 23. vanNies JA,Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-vanMil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann RheumDis. 2015; 74(5): 806-812. 24. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treat- ment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52(11): 3381-3390. 25. Markusse IM, Akdemir G, Dirven L, et al. Long-term out- comes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann InternMed. 2016; 164(8): 523-531. 26. SoutoA,Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-me- diated inflammatory diseases treated with biologics and tofaci- tinib: a systematic review andmeta-analysis of randomized con- trolled trials and long-term extension studies. Rheumatology (Oxford). 2014; 53(10): 1872-1885. 27. Lan JL, ChenYM, HsiehTY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody- positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann RheumDis. 2011; 70(10): 1719-1725. 28. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hep- atitis C infection: a systematic review. Rheumatology (Oxford). 2011; 50(9): 1700-1711. 29. Mann DL, McMurray JJ, Packer M, et al. Targeted anticy- tokine therapy in patients with chronic heart failure: results of theRandomizedEtanerceptWorldwideEvaluation (RENEWAL). Circulation. 2004; 109(13): 1594-1602. 30. Chung ES, Packer M, Lo KH, et al. Randomized, double- blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against CongestiveHeart Failure (ATTACH) trial. Cir- culation. 2003; 107(25): 3133-3140. 31. Raaschou P, Simard JF, Asker Hagelberg C, Askling J; AR- TIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016; 352: i262. 32. RaaschouP, Simard JF,HolmqvistM, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor ther- apy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013; 346: f1939. 33. Mercer LK, Lunt M, Low AL, et al.; BSRBR Control Cen- tre Consortium. Risk of solid cancer in patients exposed to anti- tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann RheumDis. 2015; 74(6): 1087-1093. 34. Silva-Fernández L, Lunt M, Kearsley-Fleet L, et al. The in- cidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2016; 55(11): 2033-2039. 35. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission taper- ing or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann RheumDis. 2016; 75(1): 45-51. 36. Emery P, HammoudehM, FitzGeraldO, et al. Sustained re- mission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014; 371(19): 1781-1792 . 28 - novembre 2018 - Minuti